Another study by Fukumoto observed that combined treatments with the HDAC6 inhibitor and anti-PD-L1 in ARID1A-mutated cancers showed efficient antitumor effects caused by improved cytotoxic T-cell activity [216]. Here, ARID1A is linked to cancer.